An exploration of therapeutic evaluation of traditional Chinese medicine in treatment of hepatic fibrosis

Xu LieMing

doi:10.3969/j.issn.1001-5256.2017.05.006

Issue 5

May 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(5): 825-828

PDF( 1536 KB)

An exploration of therapeutic evaluation of traditional Chinese medicine in treatment of hepatic fibrosis

DOI: 10.3969/j.issn.1001-5256.2017.05.006

Xu LieMing

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine & Institute of Hepatology, Shanghai University of Traditional Chinese Medicine

Received Date: 2017-01-27
Published Date: 2017-05-20

Abstract

Abstract

China has become one of the leading counties in the world to treat hepatic fibrosis with Chinese patent drugs.The therapeutic effect of traditional Chinese medicine (TCM) should be evaluated from the aspects of short-term therapeutic effect, long-term therapeutic effect, and effect of relief of symptoms.This article introduces the results of our exploration of the application of liver stiffness measurement to evaluate therapeutic effect, five-year survival rate to assess long-term therapeutic effect, and a “TCM syndrome scale” to evaluate effect of relief of symptoms, suggesting that the Chinese patent drug Fuzheng Huayu capsules/tablets have a marked clinical effect in the treatment of hepatic fibrosis.It is recommended to use serological diagnostic models, conduct prospective studies with long-term follow-up, and analyze the samples and data accumulated over a long period of time, in order to perfect the methods for evaluating the outcome of hepatic fibrosis.
- liver cirrhosis,
- Chinese patent drugs,
- treatment outcome

FullText(HTML)

References(25)

References

[1]HU XQ, ZHANG JS.Liver biopsy-practice and concepts of pathological diagnosis of hepatic fibrosis[J].J Diagn Concepts Pract, 2005, 4 (1) :71-74, 79. (in Chinese) 胡锡琪, 张锦生.肝穿刺活检-肝纤维化的病理诊断实践与理论[J].诊断学理论与实践, 2005, 4 (1) :71-74, 79.

[2]ZHANG G, HU Y, LU LG.Opportunity and challenge for diagnosis and treatment of hepatic fi brosis[J].World Chin J Dig, 2015, 23 (36) :5743-5749. (in Chinese) 张国, 胡烨, 陆伦根.肝纤维化诊治机遇与挑战[J].世界华人消化杂志, 2015, 23 (36) :5743-5749.

[3]ZHENG M, CAI WM, WENG HL, et al.ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis[J].Chin J Infect Dis, 2002, 20 (4) :225-228. (in Chinese) 郑敏, 蔡卫民, 翁红雷, 等.ROC曲线评价血清纤维化指标对诊断肝纤维化的价值[J].中华传染病杂志, 2002, 20 (4) :225-228.

[4]TAO J, PENG HQ, CAI WM, et al.Influence factors of serum fibrosis markers in liver fibrosis[J].World J Gastroenterol, 2003, 9 (11) :2497-2500.

[5]SHI YL, HE HL, WU XH, et al.The relationship between the levels of serum HA、LN、ⅣC and PⅢNP of chronic hepatitis and indexes of live fibrosis[J].Inter Med Health Guid News, 2006, 12 (8) :81-83. (in Chinese) 石亚玲, 何浩岚, 吴雪辉, 等.慢性乙型肝炎患者血清HA、LN、ⅣC及PⅢNP含量与肝纤维化程度的关系探讨[J].国际医药卫生导报, 2006, 12 (8) :81-83.

[6]LI X, ZHANG LX, CHEN YB, et al.Study on the correlation between serological indicators of hepatic fibrosis and PAPP and hepatic fibrosis[J].Chin Med Biotechnol, 2009, 4 (5) :350-354. (in Chinese) 李忻, 张立新, 陈亚宝, 等.血清肝纤维化指标及PAPP指数与肝纤维化的相关性研究[J].中国医药生物技术, 2009, 4 (5) :350-354.

[7]XUE YJ, YANG GR, ZHANG WJ, et al.Diagnostic value of detection of serum HA、LN、PCⅢ、CⅣfor liver fibrosis[J].Chin J Integr Tradit West Med Liver Dis, 2010, 20 (3) :178-179. (in Chinese) 薛永杰, 杨国嵘, 张文杰, 等.透明质酸、层粘连蛋白、Ⅲ型前胶原和Ⅳ型胶原血清学指标对肝硬化诊断的价值[J].中西医结合肝病杂志, 2010, 20 (3) :178-179.

[8]LIN LJ, XU LM.Whether the four serum markers of liver fibrosis have a reliable diagnostic value[J].Chin Hepatol, 2012, 17 (6) :433-435. (in Chinese) 林利静, 徐列明.肝纤维化四项血清标志物是否存在可信诊断价值[J].肝脏, 2012, 17 (6) :433-435.

[9]ZHANG YG, ZHAO SX, ZHOU GD, et al.Correlation of Fibro Touch and Fibro Scan with the stage of primary biliary cirrhosis[J].Chin JHepatol, 2016, 24 (12) :902-906. (in Chinese) 张玉果, 赵素贤, 周光德, 等.Fibro Touch、Fibro Scan与原发性胆汁性肝硬化分期的相关性分析[J].中华肝脏病杂志, 2016, 24 (12) :902-906.

[10]GE N, HE Q.Ultrasound elastography for evaluation of classification of liver fibrosis[J].J Clin Hepatol, 2016, 32 (12) :2379-2382. (in Chinese) 葛娜, 何茜.超声弹性成像对肝纤维化分级的评估[J].临床肝胆病杂志, 2016, 32 (12) :2379-2382.

[11]WELLS RG.The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis[J].J Clin Gastroenterol, 2005, 39 (4) :s158-s161.

[12]SANADA M, EBARA M, FUKUDA H, et al.Clinical evaluation of sonoelasticity measurement in liver using ultrasonic imaging of internal forced low frequency vibration[J].Ultrasound Med Biol, 2000, 26 (9) :1455-1460.

[13]VIZZUTTI F, ARENAL U, MARRA F, et al.Elastography for the non-invasive assessment of liver disease:limitation and future developments[J].Gut, 2009, 58 (2) :157-160.

[14]XU LM.Traditional Chinese medicine therapy and assessment of liver fibrosis[J].Drug Eval, 2007, 4 (4) :285-288. (in Chinese) 徐列明.肝纤维化中医药治疗和评价[J].药品评价, 2007, 4 (4) :285-288.

[15]LI ZJ, ZHANG XE, SU GQ, et al.Special project of basic research on traditional Chinese medicine theories in 973 Program Compilation of project achievements from 2005 to 2006[M].Beijing:China Press of Traditional Chinese Medicine, 2011:179. (in Chinese) 李振吉, 张先恩, 苏刚强, 等.973计划中医理论基础研究专项2005-2006年项目成果集[M].北京:中国中医药出版社, 2011:179.

[16]FRIEDMAN SL, BANSAL MB.Reversal of hepatic fibrosis-fact or fantasy?[J].Hepatolology, 2006, 43 (2) :s82-s88.

[17]LIN LJ, CHEN GF, GU HT, et al.Performance of Fibro Scan in evaluating the curative effects of traditional Chinese medicine on liver fibrosis[J].Chin J Hepatol, 2014, 22 (2) :113-117. (in Chinese) 林利静, 陈高峰, 顾宏图, 等.Fibro Scan评判中医药抗肝纤维化疗效的价值[J].中华肝脏病杂志, 2014, 22 (2) :113-117.

[18]SUN LD, ZHANG M, TANG Z.An analysis on prognosis in 289patients with decompensatory cirrhosis[J].Shandong Med J, 2009, 49 (32) :10-12. (in Chinese) 孙立东, 张玫, 汤哲.289例失代偿期肝硬化患者预后分析[J].山东医药, 2009, 49 (32) :10-12.

[19]SHI Y, SONG T, SHAN MJ.Clinical effect of Fuzheng Huayu capsules combined with tranexamic acid in treatment of chloasma[J].Chin J Dermato Venerol Integ Trad W Med, 2016, 15 (4) :239-240. (in Chinese) 时悦, 宋婷, 单敏洁.扶正化瘀胶囊联合氨甲环酸治疗黄褐斑的临床观察[J].中国中西医结合皮肤性病学杂志, 2016, 15 (4) :239-240.

[20]GUO XF, ZHU Q, LYU WH, et al.Primary application of chronic liver disease questionnaire in HBs Ag carriers[J].Jilin Med J, 2010, 31 (11) :1472-1474. (in Chinese) 郭新峰, 朱泉, 吕渭辉, 等.慢性肝病问卷在乙型肝炎病毒携带者中的初步试用[J].吉林医学, 2010, 31 (11) :1472-1474.

[21]ZHANG H, LIU P.A study on the thoughts and methods for quantitative research on TCM syndrome[J].Chin J Basic Med Tradit Chin Med, 2009, 15 (8) :574-576. (in Chinese) 张华, 刘平.中医证候量化研究的思路与方法探析[J].中国中医基础医学杂志, 2009, 15 (8) :574-576.

[22]WU CH, DENG QW, JI XS, et al.Preliminary use of the CLDQ in chronic hepatitis B patients[J].Chin J Clin Psychol, 2003, 11 (1) :60-62. (in Chinese) 吴创鸿, 邓启文, 纪晓抒, 等.慢性肝病问卷在慢性乙型肝炎患者中的试用[J].中国临床心理学杂志, 2003, 11 (1) :60-62.

[23]ZHANG H, LV H, HUANG PX, et al.Comparative study of TCMsyndrome scale for liver disease and chronic liver disease questionnaire based on assessment of posthepatitic cirrhosis[J].Evid Based Complement Alternat Med, 2012, 2012:496575.

[24]CHENG XJ, LU W, HOU W, et al.Diagnostic value of Fibro Test combined with Fibro Scan for liver fibrosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2014, 30 (5) :424-427. (in Chinese) 程晓静, 陆伟, 侯伟, 等.Fibro Test联合Fibro Scan对慢性乙型肝炎肝纤维化的诊断价值[J].临床肝胆病杂志, 2014, 30 (5) :424-427.

[25]LEI CD, REN Y, ZHENG SJ, et al.Diagnostic value of the APRIindex for liver fibrosis in a Chinese patients population with chronic hepatitis C acquired from blood transfusion[J].J Clin Hepatol, 2013, 29 (5) :343-347. (in Chinese) 雷成多, 任艳, 郑素军, 等.APRI指数对定西地区感染HCV的供血员肝纤维化的诊断价值[J].临床肝胆病杂志, 2013, 29 (5) :343-347.

Relative Articles

[1]	Longchuan ZHU, Wei WU, Dakai GAN, Wei ZHANG, Yizhen XU, Molong XIONG. Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2024, 40(2): 306-311. doi: 10.12449/JCH240214
[2]	Junyuan ZHU, Yifu XIA, Yanmei DU, Chunqing ZHANG. Efficacy of percutaneous transhepatic variceal embolization alone or in combination with partial splenic embolization in treatment of portal hypertensive hemorrhage in liver cirrhosis： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(1): 89-95. doi: 10.12449/JCH240116
[3]	Xinxin RONG, Yuanyuan XU, Guangde YANG, Xia WANG, Juanjuan FU, Li LI, Xiucheng PAN. Efficacy and safety of tenofovir alafenamide fumarate in patients with first-time hepatitis B virus-related decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(10): 2008-2013. doi: 10.12449/JCH241013
[4]	Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
[5]	Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021
[6]	Hongtu GU, Honglian GUI, Lieming XU, Qing GUO, Qing XIE, Changqing ZHAO. Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(2): 309-313. doi: 10.3969/j.issn.1001-5256.2021.02.013
[7]	Qianmei CAO, Zhechuan MEI. Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(10): 2439-2443. doi: 10.3969/j.issn.1001-5256.2021.10.038
[8]	Meng PeiPei, Liu Yao, Zhou MeiYue, Yu Hao, Yang YuYing, Jiang YuYong. Effect of anti-liver fibrosis Chinese patent drugs in preventing renal hypofunction associated with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2030-2034. doi: 10.3969/j.issn.1001-5256.2020.09.024
[9]	Gao BinCheng, Guo Hui, Sun Le, Zhou Jie, Jiang DongMei. Clinical effect of two targeted drugs in treatment of advanced hepatocellular carcinoma: A comparative analysis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1689-1692. doi: 10.3969/j.issn.1001-5256.2018.08.19
[10]	Zhao JingFeng, Liu Qun, Wang XiuYan, Zhang Yang, Liang LiWei, Gan Yu. Efficacy of Yunnan white medicinal powder combined with somatostatin and pantoprazole in treatment of liver cirrhosis complicated by upper gastrointestinal bleeding and its effect on inflammatory factors[J]. Journal of Clinical Hepatology, 2018, 34(1): 92-96. doi: 10.3969/j.issn.1001-5256.2018.01.019
[11]	Cui MeiLan, Jia YanSheng, Yan HuiMin, Kang HaiYan, Wang Yan, Yin ShuYing, Zheng HuanWei. Clinical effect of endoscopic dense ligation in treatment of esophageal variceal bleeding[J]. Journal of Clinical Hepatology, 2018, 34(8): 1683-1688. doi: 10.3969/j.issn.1001-5256.2018.08.018
[12]	Ge HongYan, Li PeiXia, Zhang YangYang, Wang LiLi, Wei YaoLing. Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites[J]. Journal of Clinical Hepatology, 2018, 34(1): 97-100. doi: 10.3969/j.issn.1001-5256.2018.01.020
[13]	Cui MeiLan, Jia YanSheng, Kang HaiYan, Yin ShuYing, Zheng HuanWei. Efficacy of endoscopic sclerotherapy with lauromacrogol in treatment of severe esophageal variceal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(12): 2321-2325. doi: 10.3969/j.issn.1001-5256.2017.12.013
[14]	Zhang DongXu, Luo ZiYi. Clinical effect of esophageal variceal ligation in treatment of esophageal variceal bleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(1): 76-81. doi: 10.3969/j.issn.1001-5256.2017.01.016
[15]	Ren CaiYuan, Ren Feng, Li JunFeng, Ding Mei, Chen Yu, Duan ZhongPing, Zhang HuanHu. Clinical effect of Pien Tze Huang in treatment of guinea pigs with cholecystitis induced by lithocholic acid given by gavage[J]. Journal of Clinical Hepatology, 2017, 33(5): 905-908. doi: 10.3969/j.issn.1001-5256.2017.05.023
[16]	Liang XieEr, Chen YongPeng. Role of liver fibrosis assessment in decision-making and efficacy surveillance for antiviral therapy in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2058-2061. doi: 10.3969/j.issn.1001-5256.2016.11.008
[17]	Liu TieJun. Therapeutic effect and advantages of percutaneous transhepatic variceal embolization in treatment of variceal rupture and bleeding after devascularization: an analysis of 34 cases[J]. Journal of Clinical Hepatology, 2015, 31(11): 1867-1869. doi: 10.3969/j.issn.1001-5256.2015.11.023
[18]	Huang LingYing, Zhou ZhenHua, Sun XueHua, Li Man, Zhu XiaoJun, Jin ShuGen, Zhang Xin, Gao YueQiu. Clinical efficacy of Biejiaruangan compound tablets in treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 181-184. doi: 10.3969/j.issn.1001-5256.2015.02.009
[19]	Du Ying, Fang Lei. Clinical efficacy of traditional Chinese medicine/herbal decoction combined with ursodeoxycholic acid for primary biliary cirrhosis:a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(1): 68-73. doi: 10.3969/j.issn.1001-5256.2015.01.015
[20]	Wu JiYuan, Zhang DongQin, Zhang HaiYue, Wang LuWen, Gong ZuoJiong. Efficacy and safety of transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with cirrhosis: a meta-analysis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1272-1278. doi: 10.3969/j.issn.1001-5256.2014.12.010

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	赵迪，徐佳. 中医药抗肝纤维化疗效评价的探索. 西部中医药. 2023(04): 150-153 .
2.	张涛，王之通，吴眉，张斌，朱晓骏，李运东. 消胀方联合恩替卡韦治疗乙肝肝纤维化/肝硬化疗效观察. 现代中西医结合杂志. 2023(06): 759-764 .
3.	程丹颖，郭朋，孙凤霞，王晓静，李炜，陈琴，周桂琴，王融冰，邢卉春. 恩替卡韦联合鳖甲煎丸治疗慢性乙型肝炎肝纤维化瘀血内阻证的临床疗效及其对中医证候积分的影响. 中华肝脏病杂志. 2023(06): 608-613 .
4.	范灵芝，郭峰，赵年欣. 和血柔肝方治疗慢性乙型肝炎肝纤维化肝郁脾虚证的临床研究. 云南中医中药杂志. 2021(01): 54-57 .
5.	王慧，靳菲菲，李锦秀. 恩替卡韦联合扶正化瘀片治疗慢性乙型肝炎后肝硬化的临床效果分析. 内科. 2021(04): 455-458 .
6.	韦冬珏，张凤英，周莹，王振常. 中医药联合干细胞抗肝纤维化的思路与进展. 中华中医药学刊. 2019(01): 76-81 .
7.	冯宇，刘雪梅，罗伟生，陈林，李志峰，梁健钦，张国松，奉建芳. 大孔树脂纯化荔枝核总黄酮工艺研究. 中草药. 2019(09): 2087-2093 .
8.	郑琼娜，武俏俏，马哲乐，张贤菲，干方敏，孔庆名. 低分子肝素钠对小鼠实验性肝纤维化干预作用的初步研究. 中国临床药理学与治疗学. 2019(05): 511-516 .
9.	杨晓. 中医药防治肝纤维化用药规律探讨. 内蒙古中医药. 2019(05): 135-136 .
10.	延国威，王晓忠，范灵芝，郭峰，王燕. 和血柔肝方治疗慢性乙型肝炎肝纤维化临床研究. 中国中医药信息杂志. 2019(08): 24-29 .
11.	孙凤霞，王琮，孙宁宁，徐春军. 以慢性乙型肝炎为例谈中医专业学生实习带教. 继续医学教育. 2018(03): 81-83 .
12.	陈艳，杨永平. 中医药阻断逆转肝纤维化的现状、希望与挑战. 临床肝胆病杂志. 2018(04): 689-693 . 本站查看

Other cited types(7)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2892) PDF downloads(495)

An exploration of therapeutic evaluation of traditional Chinese medicine in treatment of hepatic fibrosis

DOI: 10.3969/j.issn.1001-5256.2017.05.006